EZH2 Expression Correlates With T-Cell Infiltration in Oral Leukoplakia and Predicts Cancer Transformation
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | GANESH, Divya | |
dc.contributor.author | DAFAR, Amal | |
dc.contributor.author | NIKLASSON, Julia | |
dc.contributor.author | SANDBERG, Ingrid | |
dc.contributor.author | BRAZ-SILVA, Paulo | |
dc.contributor.author | SAPKOTA, Dipak | |
dc.contributor.author | OHMAN, Jenny | |
dc.contributor.author | GIGLIO, Daniel | |
dc.contributor.author | HASSEUS, Bengt | |
dc.date.accessioned | 2024-04-05T19:43:07Z | |
dc.date.available | 2024-04-05T19:43:07Z | |
dc.date.issued | 2023 | |
dc.description.abstract | Background/Aim: The EZH2 complex is involved in cellular proliferation and modulates the immune response in cancer. Less is known about the importance of EZH2 in precancerous lesions such as oral leukoplakia (OL). The aim of the study was to explore the association between EZH2 expression, immune activation, and cancer transformation in OL. Patients and Methods: Analyses were retrospectively performed on nine OL cases that had undergone transformation to oral squamous cell carcinoma (OSCC; OL-ca) and nine that had not undergone transformation (OL-non). EZH2-expressing cells, CD3+ and CD8+ T cells, and CD1a+ Langerhans cells were visualized with immunohistofluorescence and counted. Results: A moderate positive correlation between CD3-and EZH2-expressing and CD8-and EZH2-expressing cells in the epithelium was found (r=0.57, p=0.01; r=0.59, p=0.01). The number of EZH2-expressing cells in the epithelium of OL-ca was significantly higher compared to OL-non (p=0.0002). Cancer - free survival rates differed significantly between patients with EZH2high compared to EZH2low expression (p=0.001). EZH2high expression in OL epithelium was associated with a 13-fold higher risk for developing OSCC (HR=12.8). Conclusion: EZH2 expression in oral epithelium predicts OSCC transformation of OL and correlates with the level of T-cell infiltration. | eng |
dc.description.index | MEDLINE | |
dc.description.index | PubMed | |
dc.description.index | Scopus | |
dc.description.index | Dimensions | |
dc.description.index | WoS | |
dc.description.sponsorship | Healthcare Board, Region Vaestra Goetaland, TUA Research Funding | |
dc.description.sponsorship | Sahlgrenska Academy at the University of Gothenburg/Region Vaestra Goetaland | |
dc.description.sponsorship | Assar Gabrielsson Foundation | |
dc.description.sponsorship | Adlerbertska Foundation | |
dc.description.sponsorship | Swedish Dental Society | |
dc.description.sponsorship | Gothenburg Dental Society | |
dc.description.sponsorship | King Gustav V Jubilee Clinic Cancer Research Foundation, Goeteborg, Sweden | |
dc.description.sponsorship | Royal Society of Arts and Sciences in Gothenburg, Sweden | |
dc.identifier.citation | ANTICANCER RESEARCH, v.43, n.4, p.1533-1542, 2023 | |
dc.identifier.doi | 10.21873/anticanres.16302 | |
dc.identifier.eissn | 1791-7530 | |
dc.identifier.issn | 0250-7005 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/59260 | |
dc.language.iso | eng | |
dc.publisher | INT INST ANTICANCER RESEARCH | eng |
dc.relation.ispartof | Anticancer Research | |
dc.rights | restrictedAccess | eng |
dc.rights.holder | Copyright INT INST ANTICANCER RESEARCH | eng |
dc.subject | Oral potentially malignant disorder | eng |
dc.subject | oral cancer | eng |
dc.subject | polycomb group proteins | eng |
dc.subject | immune cells | eng |
dc.subject | biomarker | eng |
dc.subject.other | dna methylation biomarkers | eng |
dc.subject.other | progression | eng |
dc.subject.other | mechanisms | eng |
dc.subject.other | dysplasia | eng |
dc.subject.other | disease | eng |
dc.subject.wos | Oncology | eng |
dc.title | EZH2 Expression Correlates With T-Cell Infiltration in Oral Leukoplakia and Predicts Cancer Transformation | eng |
dc.type | article | eng |
dc.type.category | original article | eng |
dc.type.version | publishedVersion | eng |
dspace.entity.type | Publication | |
hcfmusp.affiliation.country | Suécia | |
hcfmusp.affiliation.country | Noruega | |
hcfmusp.affiliation.country | Árabia Saudita | |
hcfmusp.affiliation.countryiso | se | |
hcfmusp.affiliation.countryiso | sa | |
hcfmusp.affiliation.countryiso | no | |
hcfmusp.author.external | GANESH, Divya:Univ Gothenburg, Inst Odontol, Sahlgrenska Acad, Dept Oral Med & Pathol, POB 450, SE-40530 Gothenburg, Sweden | |
hcfmusp.author.external | DAFAR, Amal:Univ Gothenburg, Inst Odontol, Sahlgrenska Acad, Dept Oral Med & Pathol, POB 450, SE-40530 Gothenburg, Sweden; King Fahad Gen Hosp, Dept Oral & Maxillofacial Surg, Jeddah, Saudi Arabia | |
hcfmusp.author.external | NIKLASSON, Julia:Univ Gothenburg, Inst Odontol, Sahlgrenska Acad, Dept Oral Med & Pathol, POB 450, SE-40530 Gothenburg, Sweden | |
hcfmusp.author.external | SANDBERG, Ingrid:Univ Gothenburg, Inst Odontol, Sahlgrenska Acad, Dept Oral Med & Pathol, POB 450, SE-40530 Gothenburg, Sweden | |
hcfmusp.author.external | SAPKOTA, Dipak:Univ Oslo, Dept Oral Biol, Oslo, Norway | |
hcfmusp.author.external | OHMAN, Jenny:Univ Gothenburg, Inst Odontol, Sahlgrenska Acad, Dept Oral Med & Pathol, POB 450, SE-40530 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Clin Pathol, Gothenburg, Sweden | |
hcfmusp.author.external | GIGLIO, Daniel:Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Oncol, Gothenburg, Sweden | |
hcfmusp.author.external | HASSEUS, Bengt:Univ Gothenburg, Inst Odontol, Sahlgrenska Acad, Dept Oral Med & Pathol, POB 450, SE-40530 Gothenburg, Sweden; Publ Dent Hlth Serv, Clin Oral Med, Gothenburg, Vastra Gotaland, Sweden | |
hcfmusp.citation.scopus | 1 | |
hcfmusp.contributor.author-fmusphc | PAULO HENRIQUE BRAZ DA SILVA | |
hcfmusp.description.beginpage | 1533 | |
hcfmusp.description.endpage | 1542 | |
hcfmusp.description.issue | 4 | |
hcfmusp.description.volume | 43 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.dimensions | pub.1156568279 | |
hcfmusp.origem.pubmed | 36974822 | |
hcfmusp.origem.scopus | 2-s2.0-85150967195 | |
hcfmusp.origem.wos | WOS:000967840400002 | |
hcfmusp.publisher.city | ATHENS | eng |
hcfmusp.publisher.country | GREECE | eng |
hcfmusp.relation.reference | Balgkouranidou I, 2016, CLIN CHEM LAB MED, V54, P1385, DOI 10.1515/cclm-2015-0776 | eng |
hcfmusp.relation.reference | Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5 | eng |
hcfmusp.relation.reference | Cao W, 2011, CANCER PREV RES, V4, P1816, DOI 10.1158/1940-6207.CAPR-11-0130 | eng |
hcfmusp.relation.reference | Chen GB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00549 | eng |
hcfmusp.relation.reference | Chow A.Y., 2010, NATURE ED, V3, P7 | eng |
hcfmusp.relation.reference | Ciferri C, 2012, ELIFE, V1, DOI 10.7554/eLife.00005 | eng |
hcfmusp.relation.reference | Dong HP, 2019, CANCER RES, V79, P5587, DOI 10.1158/0008-5472.CAN-19-0428 | eng |
hcfmusp.relation.reference | Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018 | eng |
hcfmusp.relation.reference | Gannot G, 2002, BRIT J CANCER, V86, P1444, DOI 10.1038/sj.bjc.6600282 | eng |
hcfmusp.relation.reference | Gao HX, 2016, INTERACT CARDIOV TH, V23, P681, DOI 10.1093/icvts/ivw198 | eng |
hcfmusp.relation.reference | Gibbings D, 2009, J LEUKOCYTE BIOL, V86, P251, DOI 10.1189/jlb.0109040 | eng |
hcfmusp.relation.reference | Gunawan M, NAT IMMUNOL, V16, P5 | eng |
hcfmusp.relation.reference | Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMRA021902 | eng |
hcfmusp.relation.reference | He S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02187-8 | eng |
hcfmusp.relation.reference | Heichman KA, 2012, CLIN CHEM LAB MED, V50, P1707, DOI 10.1515/cclm-2011-0935 | eng |
hcfmusp.relation.reference | Hu YL, 2009, CLIN CHEM LAB MED, V47, P923, DOI 10.1515/CCLM.2009.228 | eng |
hcfmusp.relation.reference | Huang YJ, 2023, IMMUNOLOGY, V168, P30, DOI 10.1111/imm.13588 | eng |
hcfmusp.relation.reference | Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107, 10.3322/caac.21492] | eng |
hcfmusp.relation.reference | Kaech SM, 2012, NAT REV IMMUNOL, V12, P749, DOI 10.1038/nri3307 | eng |
hcfmusp.relation.reference | Kang YN, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.658241 | eng |
hcfmusp.relation.reference | Lande R, 2010, ANN NY ACAD SCI, V1183, P89, DOI 10.1111/j.1749-6632.2009.05152.x | eng |
hcfmusp.relation.reference | Lodish H, 2000, MOL CELL BIOL | eng |
hcfmusp.relation.reference | Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784 | eng |
hcfmusp.relation.reference | Markopoulou S, 2012, CLIN CHEM LAB MED, V50, P1723, DOI 10.1515/cclm-2012-0124 | eng |
hcfmusp.relation.reference | Massano J, 2006, ORAL SURG ORAL MED O, V102, P67, DOI 10.1016/j.tripleo.2005.07.038 | eng |
hcfmusp.relation.reference | Miller JS, 2019, ANNU REV CANC BIOL, V3, P77, DOI 10.1146/annurev-cancerbio-030518-055653 | eng |
hcfmusp.relation.reference | Öhman J, 2012, SCAND J IMMUNOL, V76, P39, DOI 10.1111/j.1365-3083.2012.02701.x | eng |
hcfmusp.relation.reference | Öhman J, 2015, ANTICANCER RES, V35, P311 | eng |
hcfmusp.relation.reference | Parreno V, 2022, CELL RES, V32, P231, DOI 10.1038/s41422-021-00606-6 | eng |
hcfmusp.relation.reference | Pasini D, 2016, CURR OPIN GENET DEV, V36, P50, DOI 10.1016/j.gde.2016.03.013 | eng |
hcfmusp.relation.reference | Pietersen AM, 2008, CURR OPIN CELL BIOL, V20, P201, DOI 10.1016/j.ceb.2008.01.004 | eng |
hcfmusp.relation.reference | Pinto AC, 2020, OR SURG OR MED OR PA, V129, P600, DOI 10.1016/j.oooo.2020.02.017 | eng |
hcfmusp.relation.reference | Russ BE, 2014, IMMUNITY, V41, P853, DOI 10.1016/j.immuni.2014.11.001 | eng |
hcfmusp.relation.reference | Shao FF, 2021, J LEUKOCYTE BIOL, V110, P77, DOI 10.1002/JLB.1RU0520-311R | eng |
hcfmusp.relation.reference | Sperandio M, 2023, J ORAL PATHOL MED, V52, P418, DOI 10.1111/jop.13365 | eng |
hcfmusp.relation.reference | Toraño EG, 2012, CLIN CHEM LAB MED, V50, P1733, DOI 10.1515/cclm-2011-0902 | eng |
hcfmusp.relation.reference | Tumes DJ, 2013, IMMUNITY, V39, P819, DOI 10.1016/j.immuni.2013.09.012 | eng |
hcfmusp.relation.reference | Vrtacnik P, 2014, CLIN CHEM LAB MED, V52, P589, DOI 10.1515/cclm-2013-0770 | eng |
hcfmusp.relation.reference | Warnakulasuriya S, 2020, ORAL ONCOL, V102, DOI 10.1016/j.oraloncology.2019.104550 | eng |
hcfmusp.relation.reference | Xu SB, 2023, ORAL DIS, V29, P3268, DOI 10.1111/odi.14332 | eng |
hcfmusp.relation.reference | Zhang SZ, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19020875 | eng |
hcfmusp.relation.reference | Zhang XL, 2018, J EXP MED, V215, P1365, DOI 10.1084/jem.20171417 | eng |
hcfmusp.scopus.lastupdate | 2024-05-17 | |
relation.isAuthorOfPublication | 1ace6a73-b9d8-41e6-85ff-dc13f394901a | |
relation.isAuthorOfPublication.latestForDiscovery | 1ace6a73-b9d8-41e6-85ff-dc13f394901a |